

State of Oklahoma SoonerCare

Besremi[®] (Ropeginterferon Alfa-2b-njft) Prior Authorization Form

| Member Name: | Date of Birth: | _ Member ID#: | |
|---|--------------------------|---------------|--|
| Drug Information | | | |
| Pharmacy Billing (NDC: |) Start Date (or date of | f next dose): | |
| Dose: | Regimen: | | |
| Billing Provider Information | | | |
| Pharmacy NPI: | Pharmacy Name: | | |
| Pharmacy Phone: | Pharmacy Fax: | | |
| Prescriber Information | | | |
| Prescriber NPI: | Prescriber Name: | | |
| Prescriber Phone: | Prescriber Fax: | Specialty: | |
| Criteria | | | |
| For Initial Authorization: 1. Please indicate the diagnosis and information: | | | |

- Polycythemia Vera
- A. Will Besremi[®] be used as a single agent? Yes____ No____
 If diagnosis is not listed above, please indicate diagnosis:______

Additional Information:

For Continued Authorization:

- Date of last dose:
 Does member have any evidence of progressive disease while on Besremi[®] ? Yes____ No____
- 3. Has the member experienced adverse drug reactions related to Besremi[®] therapy? Yes No

If yes, please specify adverse reactions:_____

Additional Information:

Prescriber Signature:_____ Date:_____ Date:_ the best of my knowledge. Failure to complete this form in full will result in processing delays.

| PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO: | CONFIDENTIALITY NOTICE |
|---|---|
| University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit | This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, |
| Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4 | please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction. |

11/23/2022